Listen

Add to my selection

EYLEA (aflibercept)

Medicine - Posted on Aug 03 2023

Active substance (DCI)

aflibercept

history (7)

7/19/23

EYLEA (aflibercept) - Retinopathy of prematurity (ROP)

Extension d'indication. L'essentiel Dans le traitement de la rétinopathie du prématuré (RDP) avec atteinte de la zone I (sta...

CAV :
54321

icône flèche
7/7/21

EYLEA (aflibercept) (OMD)

Key points Favourable opinion for reimbursement only in the treatment of visual impairment due to diabetic macular oedema (D...

CAV :
54321

icône flèche
7/20/16

EYLEA (aflibercept), anti-VEGF

Moderate clinical added value, as is the case with LUCENTIS, in visual impairment due to myopic choroidal neovascularisation...

CAV :
54321

icône flèche
1/6/16

EYLEA (aflibercept), anti-VEGF

Minor improvement in the management of visual impairment secondary to branch retinal vein occlusion. EYLEA now has Marketing...

CAV :
54321

icône flèche
3/18/15

EYLEA (aflibercept), anti-VEGF

Minor improvement, as is the case with LUCENTIS, in the treatment of visual impairment due to diabetic macular oedema EYLEA ...

CAV :
54321

icône flèche
5/28/14

EYLEA

-

CAV :
54321

icône flèche

4/3/13

EYLEA

-

CAV :
54321

icône flèche

Technical information

ATC code

S01LA05

Manufacturer

BAYER HEALTHCARE SAS

Presentation

EYLEA 40 mg/ml, solution injectable en flacon (code CIS : 68795701)
1 flacon en verre (CIP : 34009 267 836 7 9)

EYLEA 40 mg/ml, solution injectable en seringue préremplie (code CIS : 69613703)
1 seringue préremplie en verre (CIP : 34009 267 835 0 1)

All our publications

Diabetes mellitus